Top

Published in:

01-09-2017 | Review Article

Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis

Authors: Yeliz Yılmaz, Ayşim Güneş, Hande Topel, Neşe Atabey

Published in: Journal of Gastrointestinal Cancer | Issue 3/2017

Excerpt

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and has a poor prognosis. HCC is described as a process with a complex molecular pathogenesis. There are three common mechanisms in the initiation of HCC: (i) liver injury, which is induced by etiologic factors such as chronic viral infections with hepatitis B and hepatitis C viruses, alcohol consumption, and obesity; (ii) fibrosis and cirrhosis, which are triggered after recurrent damage and regeneration cycles; and (iii) de-regulation of one or more oncogene and/or tumor suppressor gene [1‐5]. …

Guthle M, Dollinger MM. Epidemiology and risk factors of hepatocellular carcinoma. Radiologe. 2014;54(7):654–9. doi:10.1007/s00117-014-2650-6.CrossRefPubMed

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18.CrossRefPubMed

Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140(5):1410–26. doi:10.1053/j.gastro.2011.03.006.CrossRefPubMed

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. doi:10.1056/NEJMra1001683.CrossRefPubMed

Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (5 Suppl 1):S35-50. doi:S0016508504015938.

Bruix J. Liver cancer: still a long way to go. Hepatology. 2011;54(1):1–2. doi:10.1002/hep.24468.CrossRefPubMed

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma (2012). J Hepatol 56 (4):908–943. doi:10.1016/j.jhep.2011.12.001.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9.CrossRefPubMed

Bishayee A. The role of inflammation and liver cancer. Adv Exp Med Biol. 2014;816:401–35. doi:10.1007/978-3-0348-0837-8_16.CrossRefPubMed

10.

Takaki A, Yamamoto K. Control of oxidative stress in hepatocellular carcinoma: helpful or harmful? World J Hepatol. 2015;7(7):968–79. doi:10.4254/wjh.v7.i7.968.CrossRefPubMedPubMedCentral

11.

Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181–94. doi:10.1038/nri3623 nri3623.CrossRefPubMed

12.

Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–24. doi:10.1146/annurev.med.49.1.407.CrossRefPubMed

13.

Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–63. doi:10.1200/JCO.2005.14.696.CrossRefPubMed

14.

Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505–16. doi:10.1038/nrm1962.CrossRefPubMed

15.

Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31–53.CrossRefPubMed

16.

Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goni S, et al. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology. 2008;48(4):1251–61. doi:10.1002/hep.22437.CrossRefPubMed

17.

Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goni S, Santamaria M, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med. 2009;234(7):713–25. doi:10.3181/0901-MR-12.CrossRef

18.

Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002;282(5):C947–70. doi:10.1152/ajpcell.00389.2001.CrossRefPubMed

19.

Kin M, Torimura T, Ueno T, Inuzuka S, Tanikawa K. Sinusoidal capillarization in small hepatocellular carcinoma. Pathol Int. 1994;44(10–11):771–8.PubMed

20.

Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005;94:209–31.

21.

Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol. 2008;49(6):977–84. doi:10.1016/j.jhep.2008.07.022.CrossRefPubMed

22.

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 2002;35(4):834–42. doi:10.1053/jhep.2002.32541.CrossRefPubMed

23.

Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–66. doi:10.1002/wdev.176.CrossRefPubMedPubMedCentral

24.

Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29. doi:10.1038/nrc2780 nrc2780.CrossRefPubMed

25.

Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282(37):26687–95. doi:10.1074/jbc.M704165200.CrossRefPubMed

26.

Tsunematsu H, Tatsumi T, Kohga K, Yamamoto M, Aketa H, Miyagi T, et al. Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells. Int J Cancer. 2012;130(2):356–64. doi:10.1002/ijc.26003.CrossRefPubMed

27.

Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235–53. doi:10.1038/nrd2792.CrossRefPubMedPubMedCentral

28.

Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. Biochim Biophys Acta. 2007;1773(8):1177–95. doi:10.1016/j.bbamcr.2007.01.012.CrossRefPubMed

29.

Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27(4):951–8. doi:10.1002/hep.510270409.CrossRefPubMed

30.

Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun. 1997;236(1):54–8. doi:10.1006/bbrc.1997.6840.CrossRefPubMed

31.

McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology. 1997;26(6):1484–91. doi:10.1002/hep.510260615.CrossRefPubMed

32.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2 (3):135-164. doi:10.18632/oncotarget.240.

33.

Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene. 2011;30(32):3477–88. doi:10.1038/onc.2011.160.CrossRefPubMed

34.

Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001;12(8):397–408.PubMed

35.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.CrossRefPubMed

36.

Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22(8):1178–82. doi:10.1111/j.1440-1746.2007.04997.x.CrossRefPubMed

37.

Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 1996;56(15):3436–40.PubMed

38.

Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene. 2001;20(52):7624–34. doi:10.1038/sj.onc.1204972.CrossRefPubMed

39.

Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337–40. doi:10.1126/science.1066373.CrossRefPubMed

40.

Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12(2):149–62.CrossRefPubMedPubMedCentral

41.

Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42. doi:10.1038/nrm1835.CrossRefPubMed

42.

Zhang Q, Bai X, Chen W, Ma T, Hu Q, Liang C, et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis. 2013;34(5):962–73. doi:10.1093/carcin/bgt027.CrossRefPubMed

43.

Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016;76(4):818–30. doi:10.1158/0008-5472.CAN-15-0977.CrossRefPubMed

44.

Schlaepfer DD, Hunter T. Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src. J Biol Chem. 1997;272(20):13189–95.CrossRefPubMed

45.

Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol. 2007;14(6):1835–45. doi:10.1245/s10434-007-9366-z.CrossRefPubMed

46.

Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 2003;9(14):5339–45.PubMed

47.

Dhar DK, Naora H, Yamanoi A, Ono T, Kohno H, Otani H, et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/tie pathway. Anticancer Res. 2002;22(1A):379–86.PubMed

48.

Schmitt M, Horbach A, Kubitz R, Frilling A, Haussinger D. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol. 2004;41(2):274–83. doi:10.1016/j.jhep.2004.04.035.CrossRefPubMed

49.

Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, et al. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res. 2006;66(10):5346–53. doi:10.1158/0008-5472.CAN-05-3684.CrossRefPubMed

50.

Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer. 1997;76(6):689–93.CrossRefPubMedPubMedCentral

51.

Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA. 2004;101(13):4477–82. doi:10.1073/pnas.0306068101.CrossRefPubMedPubMedCentral

52.

Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer. 2000;87(5):644–9.CrossRefPubMed

53.

Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 2013;19(9):2310–8. doi:10.1158/1078-0432.CCR-12-2791.CrossRefPubMedPubMedCentral

54.

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103. doi:10.1038/nrc3205.CrossRefPubMed

55.

DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi:10.1126/sciadv.1600200.CrossRefPubMedPubMedCentral

56.

Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 2009;174(4):1544–52. doi:10.2353/ajpath.2009.080596.CrossRefPubMedPubMedCentral

57.

Daskalow K, Pfander D, Weichert W, Rohwer N, Thelen A, Neuhaus P, et al. Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 2009;132(1):21–31. doi:10.1007/s00418-009-0590-4.CrossRefPubMed

58.

Gong L, Cui Z, Chen P, Han H, Peng J, Leng X. Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Med Oncol. 2012;29(2):909–14. doi:10.1007/s12032-011-9841-z.CrossRefPubMed

59.

Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen D, Chen T, Li J, Fan J, Cong W, Gao Q, He X (2015) Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget 6 (4):2538-2548. doi: 10.18632/oncotarget.2991.

60.

Shang RZ, Qu SB, Wang DS. Reprogramming of glucose metabolism in hepatocellular carcinoma: progress and prospects. World J Gastroenterol. 2016;22(45):9933–43. doi:10.3748/wjg.v22.i45.9933.CrossRefPubMedPubMedCentral

61.

Mertens C, Darnell JE Jr. SnapShot: JAK-STAT signaling. Cell. 2007;131(3):612. doi:10.1016/j.cell.2007.10.033.CrossRefPubMed

62.

Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23(9):1422–33. doi:10.1101/gr.154492.113.CrossRefPubMedPubMedCentral

63.

Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014;11(6):340–9. doi:10.1038/nrgastro.2014.6.CrossRefPubMed

64.

Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208. doi:10.1016/j.cell.2009.12.052.CrossRefPubMedPubMedCentral

65.

He G, Karin M. NF-kappaB and STAT3—key players in liver inflammation and cancer. Cell Res. 2011;21(1):159–68. doi:10.1038/cr.2010.183.CrossRefPubMed

66.

Wang Y, Qu A, Wang H. Signal transducer and activator of transcription 4 in liver diseases. Int J Biol Sci. 2015;11(4):448–55. doi:10.7150/ijbs.11164.CrossRefPubMedPubMedCentral

67.

Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem. 2012;287(48):40140–9. doi:10.1074/jbc.M112.348763.CrossRefPubMedPubMedCentral

68.

Farber-Katz SE, Dippold HC, Buschman MD, Peterman MC, Xing M, Noakes CJ, et al. DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3. Cell. 2014;156(3):413–27. doi:10.1016/j.cell.2013.12.023.CrossRefPubMedPubMedCentral

69.

Goodwin JF, Knudsen KE. Beyond DNA repair: DNA-PK function in cancer. Cancer Discov. 2014;4(10):1126–39. doi:10.1158/2159-8290.cd-14-0358.CrossRefPubMedPubMedCentral

70.

Pascale RM, Joseph C, Latte G, Evert M, Feo F, Calvisi DF. DNA-PKcs: a promising therapeutic target in human hepatocellular carcinoma? DNA Repair (Amst). 2016;47:12–20. doi:10.1016/j.dnarep.2016.10.004.CrossRef

71.

Zou LH, Shang ZF, Tan W, Liu XD, Xu QZ, Song M, Wang Y, Guan H, Zhang SM, Yu L, Zhong CG, Zhou PK (2015) TNKS1BP1 functions in DNA double-strand break repair though facilitating DNA-PKcs autophosphorylation dependent on PARP-1. Oncotarget 6 (9):7011-7022. doi:10.18632/oncotarget.3137.

72.

Evert M, Frau M, Tomasi ML, Latte G, Simile MM, Seddaiu MA, et al. Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. Br J Cancer. 2013;109(10):2654–64. doi:10.1038/bjc.2013.606.CrossRefPubMedPubMedCentral

73.

Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, et al. DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res. 2015;21(4):925–33. doi:10.1158/1078-0432.ccr-14-0842.CrossRefPubMed

74.

Leu JI, George DL. Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev. 2007;21(23):3095–109. doi:10.1101/gad.1567107.CrossRefPubMedPubMedCentral

75.

Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, et al. Non-cell-autonomous tumor suppression by p53. Cell. 2013;153(2):449–60. doi:10.1016/j.cell.2013.03.020.CrossRefPubMedPubMedCentral

76.

Amaral JD, Castro RE, Steer CJ, Rodrigues CM. p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis. Trends Mol Med. 2009;15(11):531–41. doi:10.1016/j.molmed.2009.09.005.CrossRefPubMed

77.

Meng X, Franklin DA, Dong J, Zhang Y. MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res. 2014;74(24):7161–7. doi:10.1158/0008-5472.can-14-1446.CrossRefPubMedPubMedCentral

78.

Brown CJ, Cheok CF, Verma CS, Lane DP. Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci. 2011;32(1):53–62. doi:10.1016/j.tips.2010.11.004.CrossRefPubMed

79.

Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8. doi:10.1038/ncb2641.CrossRefPubMed

80.

Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene. 2008;27(50):6507–21. doi:10.1038/onc.2008.315.CrossRefPubMedPubMedCentral

81.

Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, Francois C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A (2015) The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 356 (2 Pt B):971-977. doi:10.1016/j.canlet.2014.11.014.CrossRefPubMed

82.

Ozturk M, Arslan-Ergul A, Bagislar S, Senturk S, Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. Cancer Lett. 2009;286(1):103–13. doi:10.1016/j.canlet.2008.10.048.CrossRefPubMed

83.

Ilagan MX, Kopan R. SnapShot: notch signaling pathway. Cell. 2007;128(6):1246. doi:10.1016/j.cell.2007.03.011.CrossRefPubMed

84.

Katsube K, Sakamoto K. Notch in vertebrates—molecular aspects of the signal. Int J Dev Biol. 2005;49(2–3):369–74. doi:10.1387/ijdb.041950kk.CrossRefPubMed

85.

D'Souza B, Meloty-Kapella L, Weinmaster G. Canonical and non-canonical Notch ligands. Curr Top Dev Biol. 2010;92:73–129. doi:10.1016/s0070-2153(10)92003-6.CrossRefPubMedPubMedCentral

86.

Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216–33. doi:10.1016/j.cell.2009.03.045.CrossRefPubMedPubMedCentral

87.

Tanimizu N, Miyajima A. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J Cell Sci. 2004;117(Pt 15):3165–74. doi:10.1242/jcs.01169.CrossRefPubMed

88.

Fiorotto R, Raizner A, Morell CM, Torsello B, Scirpo R, Fabris L, et al. Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. J Hepatol. 2013;59(1):124–30. doi:10.1016/j.jhep.2013.02.025.CrossRefPubMedPubMedCentral

89.

Morell CM, Fiorotto R, Fabris L, Strazzabosco M. Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. Clin Res Hepatol Gastroenterol. 2013;37(5):447–54. doi:10.1016/j.clinre.2013.05.008.CrossRefPubMed

90.

Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A, et al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int. 2007;27(7):997–1007. doi:10.1111/j.1478-3231.2007.01544.x.CrossRefPubMed

91.

Gil-Garcia B, Baladron V. The complex role of NOTCH receptors and their ligands in the development of hepatoblastoma, cholangiocarcinoma and hepatocellular carcinoma. Biol Cell. 2016;108(2):29–40. doi:10.1111/boc.201500029.CrossRefPubMed

92.

Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 2012;143(6):1660–1669 e1667. doi:10.1053/j.gastro.2012.09.002.CrossRefPubMed

93.

Luo J, Wang P, Wang R, Wang J, Liu M, Xiong S, Li Y, Cheng B (2016) The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. Oncotarget 7 (8):9525-9537. doi:10.18632/oncotarget.6672.

94.

Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 2013;19(11):1410–22. doi:10.1038/nm.3389.CrossRefPubMed

95.

Chen MH, Wilson CW, Chuang PT. SnapShot: hedgehog signaling pathway. Cell. 2007;130(2):386. doi:10.1016/j.cell.2007.07.017.CrossRefPubMed

96.

Zheng X, Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, et al. The transcription factor GLI1 mediates TGFbeta1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One. 2012;7(11):e49581. doi:10.1371/journal.pone.0049581.CrossRefPubMedPubMedCentral

97.

Wang Y, Han C, Lu L, Magliato S, Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology. 2013;58(3):995–1010. doi:10.1002/hep.26394.CrossRefPubMed

98.

Lu JT, Zhao WD, He W, Wei W. Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway. Acta Pharmacol Sin. 2012;33(5):691–700. doi:10.1038/aps.2012.24.CrossRefPubMedPubMedCentral

99.

Xu QR, Zheng X, Zan XF, Yao YM, Yang W, Liu QG (2012) [Gli1 expression and its relationship with the expression of Shh, Vimentin and E-cadherin in human hepatocellular carcinoma]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28 (5):536–539.

100.

Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis. 2006;27(4):748–57. doi:10.1093/carcin/bgi292.CrossRefPubMed

101.

Tada M, Kanai F, Tanaka Y, Tateishi K, Ohta M, Asaoka Y, et al. Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res. 2008;14(12):3768–76. doi:10.1158/1078-0432.ccr-07-1181.CrossRefPubMed

102.

Chan IS, Guy CD, Chen Y, Lu J, Swiderska-Syn M, Michelotti GA, et al. Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res. 2012;72(24):6344–50. doi:10.1158/0008-5472.can-12-1068.CrossRefPubMedPubMedCentral

103.

Arzumanyan A, Sambandam V, Clayton MM, Choi SS, Xie G, Diehl AM, et al. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res. 2012;72(22):5912–20. doi:10.1158/0008-5472.can-12-2329.CrossRefPubMedPubMedCentral

104.

Pereira Tde A, Witek RP, Syn WK, Choi SS, Bradrick S, Karaca GF, et al. Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Investig. 2010;90(12):1690–703. doi:10.1038/labinvest.2010.147.CrossRefPubMed

105.

Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One. 2011;6(9):e23943. doi:10.1371/journal.pone.0023943.CrossRefPubMedPubMedCentral

106.

Jeng KS, Jeng CJ, Jeng WJ, Sheen IS, Chang CF, Hsiau HI, et al. Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma. Am J Surg. 2015;210(3):554–60. doi:10.1016/j.amjsurg.2015.03.001.CrossRefPubMed

107.

Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer. 2014;3(2):71–84. doi:10.1159/000343863.CrossRefPubMedPubMedCentral

108.

Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67(22):10831–9. doi:10.1158/0008-5472.CAN-07-0908.CrossRefPubMed

109.

Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50(2):472–80. doi:10.1002/hep.22989.CrossRefPubMed

110.

Su R, Nan H, Guo H, Ruan Z, Jiang L, Song Y, et al. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma. Hepatol Res. 2016;46(13):1380–91. doi:10.1111/hepr.12687.CrossRefPubMed

111.

Firtina Karagonlar Z, Koc D, Sahin E, Avci ST, Yilmaz M, Atabey N, et al. Effect of adipocyte-secreted factors on EpCAM+/CD133+ hepatic stem cell population. Biochem Biophys Res Commun. 2016;474(3):482–90. doi:10.1016/j.bbrc.2016.04.137.CrossRefPubMed

112.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–8. doi:10.1158/0008-5472.CAN-06-1377.CrossRefPubMed

113.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al., Group SIS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. doi:10.1056/NEJMoa0708857.CrossRefPubMed

114.

Firtina Karagonlar Z, Koc D, Iscan E, Erdal E, Atabey N. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci. 2016;107(4):407–16. doi:10.1111/cas.12891.CrossRefPubMedPubMedCentral

115.

Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T (2015) Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget 6 (14):12340-12356. doi: 10.18632/oncotarget.3656.

116.

Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63. doi:10.1016/S1470-2045(12)70490-4.CrossRefPubMed

117.

Finn RS. Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis. 2013;33(Suppl 1):S11–9. doi:10.1055/s-0033-1333632.CrossRefPubMed

118.

Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992–8. doi:10.1200/JCO.2007.15.9947.CrossRefPubMed

119.

Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898–903. doi:10.1200/JCO.2005.04.9130.CrossRefPubMed

120.

Yamaguchi H, Chang SS, Hsu JL, Hung MC. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene. 2014;33(9):1073–81. doi:10.1038/onc.2013.74.CrossRefPubMed

121.

Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem. 2000;275(12):8806–11.CrossRefPubMed

122.

Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S, et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res. 2008;6(1):139–50. doi:10.1158/1541-7786.MCR-07-0236.CrossRefPubMedPubMedCentral

123.

Nath D, Williamson NJ, Jarvis R, Murphy G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci. 2001;114(Pt 6):1213–20.PubMed

124.

Korhan P, Erdal E, Kandemis E, Cokakli M, Nart D, Yilmaz F, et al. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One. 2014;9(8):e105278. doi:10.1371/journal.pone.0105278.CrossRefPubMedPubMedCentral

125.

Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, Karademir S, et al. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 2012;11:64. doi:10.1186/1476-4598-11-64.CrossRefPubMedPubMedCentral

126.

Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis rev. 1990;9(3):203–26.CrossRefPubMed

127.

Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125(1):89–97.CrossRefPubMed

128.

Suzuki M, Sugimoto K, Tanaka J, Tameda M, Inagaki Y, Kusagawa S, et al. Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res. 2010;30(12):5055–61.PubMed

129.

Kemp LE, Mulloy B, Gherardi E. Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. Biochem Soc Trans. 2006;34(Pt 3):414–7. doi:10.1042/BST0340414.CrossRefPubMed

130.

Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N. Heparin inhibits hepatocyte growth factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One. 2012;7(8):e42717. doi:10.1371/journal.pone.0042717.CrossRefPubMedPubMedCentral

131.

Iscan E, Gunes A, Korhan P, Yilmaz Y, Erdal E, Atabey N. The regulatory role of heparin on c-Met signaling in hepatocellular carcinoma cells. J Cell Commun Signal. 2016; doi:10.1007/s12079-016-0368-0.CrossRefPubMedPubMedCentral

Title: Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis
Authors: Yeliz Yılmaz
Ayşim Güneş
Hande Topel
Neşe Atabey
Publication date: 01-09-2017
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 3/2017
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-9958-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2017

Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors

Is That Possible to Stop or Cease the NASH to Turn into HCC?

Validation of a Liver Index and Its Significance for HCC Aggressiveness

Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others

Liver Transplantation for Hepatocellular Carcinoma: Kent Hospital Experience

HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page